Epitope First: Immunohistochemistry as a Translational Tool in Drug Development Part 6

Signal First or Specificity First

Resolving a Common Conflict in IHC Assay Development

Abstract

In immunohistochemistry (IHC) assay development, particularly in mouse-on-mouse systems, disagreements frequently arise regarding whether primary antibody signal strength or background control should be prioritized first. This paper outlines the rationale behind both perspectives, explains why the conflict exists, and proposes a practical compromise that preserves biological truth while satisfying development imperatives. The goal is not to declare a winner, but to align disciplines around assay interpretability and translational validity.

Introduction

IHC occupies a unique position in drug development. It is both a biological discovery tool and a measurement assay, and the transition between these roles is rarely clean. As a result, different stakeholders approach assay optimization with different priorities. Two common positions emerge:

• The “signal first” approach, typically driven by principal investigators (PIs)
• The “specificity first” approach, typically driven by histotechnologists

Both are defensible. Conflict arises when the assumptions behind each approach are not made explicit.

The PI Perspective: Why Signal Comes First

From the PI’s standpoint, the first existential question of an IHC assay is simple:

Does the target produce detectable signal at all?

Core concerns driving the PI position:

1. Risk of false negatives
   In early development, failing to detect a real but low-abundance target can prematurely eliminate a viable drug target or biomarker.
2. Sensitivity bias from other assay modalities
   PIs are often trained in Western blotting, ELISA, flow cytometry, or sequencing, where signal amplification is generally safer and background is easier to model or subtract.
3. Project continuity pressure
   A weak or absent signal can stall a program. Strong signal, even if imperfect, keeps development moving.
4. Assumption that background is correctable
   From this view, background is a technical nuisance that can be addressed later with blocking, dilution, or analysis thresholds.

PI logic in one sentence:

“If we don’t see signal early, we may never know whether the biology is real.”

The Histotechnologist Perspective: Why Background Must Be Controlled First

Histotechnologists approach IHC as a spatial, tissue-contextual assay where signal and background are inseparable.

Core concerns driving the histotech position:

1. Signal and background scale together
   In mouse-on-mouse systems, increasing primary concentration or detection sensitivity increases:
   • true target signal
   • endogenous IgG binding
   • Fc receptor staining
   • polymer/detection stickiness
2. False positives are visually convincing
   Unlike numeric assays, IHC artifacts can closely mimic true biological patterns, especially membranous or stromal staining.
3. Interpretability is the limiting factor
   An assay with strong signal but ambiguous specificity is worse than no assay at all, because it can mislead decision-making.
4. Downstream accountability
   Histotechnologists are responsible for ensuring that what is seen on the slide can be defended to pathologists, regulators, and reviewers.

Histotech logic in one sentence:

“A strong signal that cannot be distinguished from background is not evidence.”

Why the Conflict Exists

The disagreement is not about competence or rigor. It is about failure modes.

• PIs are primarily guarding against missing real biology
• Histotechnologists are primarily guarding against believing false biology

Both risks are real. The conflict arises when one risk is addressed at the expense of the other.

The Practical Compromise: Signal Viability Before Signal Optimization

The resolution is not to choose one philosophy over the other, but to sequence them correctly.

Step 1: Establish signal viability, not maximal signal

• Use a reasonable, mid-range blocking condition
• Use the PI-required detection system
• Include essential controls (no primary, matched isotype)
• Answer only one question:

Can this antibody produce a plausible, localized signal above baseline?

This satisfies the PI’s need to confirm the assay is alive.

Step 2: Optimize background to restore interpretability

• Systematically vary blocking parameters
• Evaluate performance on known positive and known negative tissues
• Determine whether the detection system can be made interpretable

This satisfies the histotechnologist’s responsibility to preserve meaning.

Step 3: Optimize primary concentration within the interpretable window

• Increase concentration or incubation only after specificity boundaries are known
• Avoid amplification strategies that collapse signal and background into ambiguity

Why This Compromise Works

• It prevents premature abandonment of valid targets
• It prevents false confidence in artifact-driven signal
• It produces data that are interpretable by pathologists
• It creates a defensible audit trail for assay decisions

Most importantly, it reframes optimization as risk management, not preference.

Conclusion

The “signal first” versus “specificity first” debate is a symptom of IHC’s dual identity as both discovery tool and diagnostic assay. Both perspectives are valid within their domains. Successful assay development requires acknowledging these differences and sequencing decisions accordingly.

The correct question is not “Which comes first?” but rather:

At this stage of development, which failure would be more damaging?

When that question is answered explicitly, the conflict resolves itself.

• • •